Glaucoma

Metabolomics reflects the physiological state of a tissue and provides information about interactions between genetics, environment and lifestyle

Investigators assessed the XEN45 implant alone and in combination with phacoemulsification

Early results indicate that trained optometrists delivered safe and effective laser treatments

This year’s meeting will take place in Ireland’s technology and business hub

Three approaches to examination give a comprehensive overview

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Proteins common to Alzheimer disease play a significant role in glaucoma

Innovative therapies scale up to meet needs of a growing patient population

The company made its CE Mark announcement during the ESCRS Winter Meeting

According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields

Standalone, minimally-invasive glaucoma treatments

The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)

Prevent Blindness will offer downloadable fact sheets, shareable social media graphics and educational videos for patients

In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices

Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma

More testing is needed to ensure accuracy across different groups

Results showed that the PAUL Glaucoma Implant is an effective glaucoma drainage device that provides effective IOP lowering, similar to that achieved with the Baerveldt Glaucoma Implant, but with lower rates of complications

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

As part of the meeting’s MIGS programme, Keith Barton, MD, FRCP, FRCS, FRCOphth, shared data from the iTrack™ Global Data Registry

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

According to the company, the deal expands its European footprint into Spain and Portugal.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

The open-access tool is the official registry partner of the European Glaucoma Society.

Preliminary results indicate significant improvement for patients and ‘very good safety profile’